Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
复制标题
DOI：
10.1002/ijc.31335
复制
发表时间：
2018-08-01
影响因子：
6.4
通讯作者：
Anderson KS
中科院分区：
文献类型：
--
作者：
Kaaks R;Fortner RT;Hüsing A;Barrdahl M;Hopper M;Johnson T;Tjønneland A;Hansen L;Overvad K;Fournier A;Boutron-Ruault MC;Kvaskoff M;Dossus L;Johansson M;Boeing H;Trichopoulou A;Benetou V;La Vecchia C;Sieri S;Mattiello A;Palli D;Tumino R;Matullo G;Onland-Moret NC;Gram IT;Weiderpass E;Sánchez MJ;Navarro Sanchez C;Duell EJ;Ardanaz E;Larranaga N;Lundin E;Idahl A;Jirström K;Nodin B;Travis RC;Riboli E;Merritt M;Aune D;Terry K;Cramer DW;Anderson KS
免疫蛋白质组学筛选已经鉴定出几种可能具有侵袭性上皮性卵巢癌诊断能力的肿瘤相关自身抗体（AAb），其中P53蛋白的AAb和癌症睾丸抗原（CTAG）是突出的例子。然而，这些AAb的早期检测潜力在前瞻性研究中尚未得到充分探索。我们对来自欧洲EPIC队列的194例卵巢癌患者和705例匹配对照进行了CTAG 1A、CTAG 2、P53和NUDT 11蛋白的AAbs ELISA测量，使用在诊断前36个月在常规护理下收集的血清样本。采用电化学发光法测定CA 125。通过采血和诊断之间的提前时间分层计算诊断区分统计量。在提前时间≤6个月的情况下，特异性为0.98的卵巢癌检测灵敏度（SE 98）从CTAG 1A、CTAG 2和NUDT 1的0.19 [95% CI 0.08-0.40]变化到P53的0.23 [0.10-0.44]（高级别浆液性肿瘤为0.33 [0.11-0.68]）。然而，在较长的前置时间，这些AAb标志物区分未来卵巢癌病例与对照的能力迅速下降;在前置时间>1年时，SE 98估计值接近于零（所有侵袭性病例，范围：0.01-0.11）。与单独的CA 125相比，AAbs和CA 125的联合logistic回归评分在相同的特异性水平下没有提高检测灵敏度。因此，这些选择的AAbs作为卵巢癌的标记物的附加值超过CA 125用于早期检测是有限的。
Immuno-proteomic screening has identified several tumor-associated auto-antibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53, and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08–0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10–0.44] for P53 (0.33 [0.11–0.68] for high-grade serous tumors). However, at longer lead-times the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01–0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-09-0880
发表时间：
2010-03
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Anderson KS;Wong J;Vitonis A;Crum CP;Sluss PM;Labaer J;Cramer D
通讯作者：
Cramer D
DOI：
10.1002/prca.201500096
发表时间：
2016-07
期刊：
Proteomics. Clinical applications
影响因子：
--
作者：
Katchman BA;Barderas R;Alam R;Chowell D;Field MS;Esserman LJ;Wallstrom G;LaBaer J;Cramer DW;Hollingsworth MA;Anderson KS
通讯作者：
Anderson KS
影响因子：
3.7
作者：
Tang ZM;Ling ZG;Wang CM;Wu YB;Kong JL
通讯作者：
Kong JL
自身抗体特征：早期癌症检测的进步和观点。
影响因子：
5.3
作者：
Desmetz C;Mange A;Maudelonde T;Solassol J
通讯作者：
Solassol J
DOI：
10.1016/s0140-6736(15)01224-6
发表时间：
2016-03-05
期刊：
Lancet (London, England)
影响因子：
--
作者：
Jacobs IJ;Menon U;Ryan A;Gentry-Maharaj A;Burnell M;Kalsi JK;Amso NN;Apostolidou S;Benjamin E;Cruickshank D;Crump DN;Davies SK;Dawnay A;Dobbs S;Fletcher G;Ford J;Godfrey K;Gunu R;Habib M;Hallett R;Herod J;Jenkins H;Karpinskyj C;Leeson S;Lewis SJ;Liston WR;Lopes A;Mould T;Murdoch J;Oram D;Rabideau DJ;Reynolds K;Scott I;Seif MW;Sharma A;Singh N;Taylor J;Warburton F;Widschwendter M;Williamson K;Woolas R;Fallowfield L;McGuire AJ;Campbell S;Parmar M;Skates SJ
通讯作者：
Skates SJ